Free press releases distribution network?

Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG Announces Positive Data from First US Phase III Trial of Varisolve® - Study meets all primary, secondary and tertiary endpoints (LSE: BGC) -
BTG Announces Positive Data from First US Phase III Trial of Varisolve®


PRZOOM - /newswire/ - London, United Kingdom, 2012/01/30 - Study meets all primary, secondary and tertiary endpoints (LSE: BGC) - LSE: BTG

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BTG plc, the specialist healthcare company, today announces the successful outcome of VANISH-2, the first of two US pivotal Phase III studies comparing the safety and efficacy of Varisolve® (polidocanol endovenous microfoam (PEM)) with placebo in patients with symptomatic and visible varicose veins and saphenofemoral junction incompetence. Both pivotal Phase III studies are fully recruited, and all patients have been treated, reached the primary endpoint and are in long-term follow-up.

The study met all primary, secondary and tertiary efficacy endpoints. Patients treated with PEM (0.5% or 1.0% dose concentrations) demonstrated a statistically significant improvement in symptoms, the study primary endpoint as measured by the VVSymQ™ score, compared with patients who received placebo (p < 0.0001). The VVSymQ™ score is a patient-reported outcome measure of varicose vein symptoms developed and validated by BTG in accordance with FDA guidelines. The study’s co-secondary endpoint, improvement of appearance as measured by both a patient-reported outcome (PA-V3™) and by a blinded independent panel review of photographs (IPR-V3™), was also met. Patients treated with PEM (0.5 or 1.0% dose concentrations) reported a statistically significant improvement in appearance in both the PA-V3 and IPR-V3 scores compared with patients who received placebo (p < 0.0001 and p < 0.0001, respectively).

The three tertiary endpoints, response to treatment as determined by duplex ultrasound, change in the Venous Clinical Severity Score and Quality of Life as measured by the modified VEINES-Sym/QOL questionnaire, were all statistically significantly better for patients treated with PEM (0.5% or 1.0% dose concentrations) compared to patients who received placebo (all at p < 0.0001).

In this study and across the whole Phase III programme, in which 590 patients received PEM and there were 984 PEM treatments in total, there were no serious or unexpected adverse events associated with the use of PEM. There were no cerebrovascular events or pulmonary emboli reported in any study. Chemically induced thrombosis occurred in 5.8% of PEM treatments, of which 0.5% were symptomatic deep vein thrombosis of the upper leg and 0.7% of the lower leg, respectively. The safety profile of PEM was consistent with previous clinical studies.

VANISH-2 investigator Dr Kenneth Todd, MD, South East Vein and Laser Centre, and American College of Phlebology Committee Member, said: “VANISH-2 is an important study because it is the first time patient benefit has been shown using a patient-reported outcome measure in a randomised controlled clinical trial in patients with varicose veins. If Varisolve® demonstrates the same sort of significant improvement in symptoms and acceptable safety profile in the additional Phase III trials, it should provide an important new treatment option for varicose veins.It has been a great trial to be part of as my patients have been so happy with their results.”

Louise Makin, BTG’s CEO, commented: “We are delighted with the successful outcome of VANISH-2. We look forward to the results of the second pivotal Phase III trial, VANISH-1, and to the results of study VV017 in which Varisolve® is used following heat ablation. These are both due in the first half of 2012, and we are on track to submit our US regulatory application by the end of 2012.”

VANISH-2 included 235 patients who were randomised to receive treatment with one of three dose concentrations (0.125%, 0.5% or 1.0%) of PEM (n = 176) or “vehicle”, effectively a placebo comparator (n = 59). The primary endpoint of the study was an improvement in symptoms recorded by patients using a novel patient-reported outcomes instrument, VVSymQ™. Patients scored a variety of symptoms such as swelling and aching using a daily electronic diary for 10 days prior to treatment (baseline) and for an additional 10 days prior to the primary endpoint at eight weeks following treatment. The secondary endpoint was the improvement in appearance and was measured both by patients, who used another novel, validated patient-reported outcome instrument, PA-V3™ and by an independent panel review of before and after photographs in a blinded setting using a validated clinician-reported instrument, IPR-V3™.

PEM is a unique patent-protected drug/device combination. It produces highly uniform CO2/O2 polidocanol endovenous microfoam engineered to improve safety and efficacy in the treatment of varicose veins. It is injected directly into the incompetent vein under ultrasound guidance, where it first displaces blood and then the polidocanol chemically ablates the inner lining of the vein wall, causing the vein to close. A compression bandage is applied to the leg for a period of approximately two weeks. If approved, this would be the first non-surgical, comprehensive treatment for varicose veins above and below the knee.

Forward Looking Statements
This communication may contain forward-looking statements with respect to the financial condition, results of operations, businesses and prospects of BTG plc (“BTG”). These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by these forward-looking statements. Any of the assumptions underlying these forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in the forward-looking statements may not actually be achieved. Nothing contained in this press release or communicated verbally should be construed as a profit forecast or profit estimate. Investors or other recipients are cautioned not to place undue reliance on any forward-looking statements contained herein. BTG undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances. Neither this communication nor any verbal communication shall constitute an invitation or inducement to any person to subscribe for or otherwise acquire securities in BTG.

For further information contact:

Andy Burrows, Director of Investor Relations
T: +44 (0)20 7575 1741 - Mobile: +44 (0)7990 530605

Rolf Soderstrom, Chief Financial Officer
T: +44 (0)20 7575 0000

Ben Atwell, FTI Consulting
T: +44 (0)20 7831 3113

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: Biocompatibles UK Ltd / BTG Plc


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

BTG Announces Positive Data from First US Phase III Trial of Varisolve®

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
BTG Plc |
Contact: Press Office - 
+44(0)20 7575 1513 media[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Press Releases From Biocompatibles UK Ltd / BTG Plc / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  Intrinsic Executive Search Ltd

Visit  NAKIVO, Inc.

  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today